Table 11KQ3—Initial and target dosing regimens

Study, yearGroupInitial DoseTarget Dose
MARCATOR, 199553Cilazapril

Placebo
1mg on the first evening, then 2mg/d (divided twice daily) or 2.5mg on the first evening followed by 10–20mg/d (divided twice daily)20mg/d
APRES, 200054Ramipril
Placebo
2.5mg × 1 dose, then 5mg/d × 1 month, then 10mg/d10mg/d
Kondo et al, 200155Quinapril
Control
10–20mg/d20mg/d
PARIS, 200156Quinapril
Placebo
20mg × 1 dose, then 40mg/d40mg/d
QUIET, 200157Quinapril
Placebo
10mg × 1 dose, then 20mg/d20mg/d
AACHEN, 200658Candesartan
Placebo
32mg/d32mg/d
IMAGINE, 200859Quinapril
Placebo
10–20mg/d (according to investigator), then increased to 40mg/d if tolerated40 mg/d

From: Results

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet].
Comparative Effectiveness Reviews, No. 18.
Coleman CI, Baker WL, Kluger J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.